Trial · NCT02329847
Participant flow24
How many started, completed or left each group, period by period.
1 to 20 of 24
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | 7 | |
| Overall Study | STARTED | Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 7 | |
| Overall Study | STARTED | Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | 36 | |
| Overall Study | STARTED | Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 35 | |
| Overall Study | STARTED | Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 39 | |
| Overall Study | STARTED | Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 20 | |
| Overall Study | Treated (Safety Analysis Set) | Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | 7 | |
| Overall Study | Treated (Safety Analysis Set) | Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 7 | |
| Overall Study | Treated (Safety Analysis Set) | Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | 35 | |
| Overall Study | Treated (Safety Analysis Set) | Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 35 | |
| Overall Study | Treated (Safety Analysis Set) | Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 37 | |
| Overall Study | Treated (Safety Analysis Set) | Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 20 | |
| Overall Study | COMPLETED | Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | 0 | |
| Overall Study | COMPLETED | Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 0 | |
| Overall Study | COMPLETED | Cohort B1 (CLL/SLL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | 1 | |
| Overall Study | COMPLETED | Cohort B2 (FL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 0 | |
| Overall Study | COMPLETED | Cohort B3 (DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 0 | |
| Overall Study | COMPLETED | Cohort B4 (Richter Syndrome): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 0 | |
| Overall Study | NOT COMPLETED | Cohort A1 (CLL/FL/DLBCL): Ibrutinib 420 mg + Nivolumab 3 mg/kg | 7 | |
| Overall Study | NOT COMPLETED | Cohort A2 (FL/DLBCL): Ibrutinib 560 mg + Nivolumab 3 mg/kg | 7 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02329847/flow